A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece...
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient access DENVER, COLORADO / ACCESS Newswire / January...
Aytu BioPharma (Nasdaq: AYTU) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. This fireside chat was recorded during the Lytham Partners 2026 Investor...
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse...
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...